NCT03181126 - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

November 11, 2020

Study Completion Date

November 14, 2020

Conditions

Acute Lymphoblastic Leukemia (ALL)Lymphoblastic Lymphoma

Interventions

DRUG

Navitoclax

tablet

DRUG

Chemotherapy

peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)

DRUG

Venetoclax

tablet

Trial Locations (15)

3004

Alfred Hospital /ID# 169576, Melbourne

3050

Victorian Comprehensive Cancer /ID# 165710, Melbourne

3052

Royal Children's Hospital /ID# 163322, Melbourne

38105

St Jude Children's Research Hospital /ID# 163335, Memphis

43205

Nationwide Childrens Hospital /ID# 163372, Columbus

45229

Cincinnati Children's Hospital /ID# 164619, Cincinnati

53705

University of Wisconsin-Madiso /ID# 165691, Madison

60637

University of Chicago /ID# 163369, Chicago

63110

Washington University-School of Medicine /ID# 165689, St Louis

91010

City of Hope /ID# 169029, Duarte

94304

LPCH Stanford /ID# 163337, Palo Alto

97239

Oregon Health and Science University /ID# 165690, Portland

27514-4220

Univ NC Chapel Hill /ID# 163509, Chapel Hill

75390-7208

UT Southwestern Medical Center /ID# 163346, Dallas

77030-4000

MD Anderson Cancer Center at Texas Medical Center /ID# 163327, Houston